TB-500 Dosing in Hepatic Impairment: What Women Need to Know

What Is TB-500 and How Does It Work?

TB-500 is a synthetic 17-amino-acid fragment derived from thymosin beta-4, a naturally occurring 43-amino-acid polypeptide found in nearly every cell in your body. Thymosin beta-4 was first isolated from thymic tissue in the 1980s, but TB-500 specifically refers to the active fragment spanning amino acids 17 to 23, sometimes called the actin-binding domain. This fragment carries most of the tissue-repair activity of the parent molecule.

The Actin-Sequestering Mechanism

TB-500 works by binding to G-actin (globular actin), the monomeric form of the protein that builds your cytoskeleton. By sequestering G-actin, it shifts the intracellular actin equilibrium in ways that promote cell migration, angiogenesis, and differentiation of progenitor cells. In plain terms, it tells damaged cells to move, divide, and reconnect.

Goldstein et al. (2012) in the Annals of the New York Academy of Sciences summarized animal and early human data showing thymosin beta-4 promotes cardiac repair after myocardial infarction, reduces scar tissue formation, and recruits epicardial progenitor cells. The cardiac data in humans remains small and inconclusive, but it anchors the mechanistic rationale that broader tissue-repair proponents cite.

Why Women Ask About TB-500

Women seeking TB-500 typically fall into a few categories: athletes or active women recovering from musculoskeletal injury, women with inflammatory conditions such as endometriosis or autoimmune arthritis looking for adjunct repair support, and women in perimenopause or post-menopause experiencing slower tissue recovery. Some practitioners also discuss it in the context of PCOS-related metabolic inflammation, though no trial evidence supports this use.

The sex-specific dimension matters here. Estrogen itself has actin-remodeling properties in connective tissue, and estrogen decline during perimenopause alters the baseline tissue-repair environment that TB-500 is theorized to influence. This biological interaction has not been studied in any trial.

TB-500 Pharmacokinetics: What the Liver Does

Peptides like TB-500 are not processed the way small-molecule drugs are. They are not primarily metabolized by cytochrome P450 enzymes, so the CYP-based hepatic impairment frameworks that apply to drugs like estradiol or metformin do not translate directly. Instead, peptides are degraded by:

• Proteolytic enzymes present in blood, tissues, and the liver itself
• Renal filtration, for fragments small enough to pass the glomerulus
• Hepatic peptidase activity, including carboxypeptidases and aminopeptidases expressed in liver parenchyma

Because TB-500 is a 17-amino-acid fragment with a molecular weight of roughly 2,000 daltons, it sits at the borderline of renal filtration capacity. The liver contributes to its clearance through hepatic peptidases, and reduced hepatic mass or function in liver disease slows that clearance pathway.

No Formal Pharmacokinetic Studies Exist

This is the central evidence gap you need to understand before any decision. There are no published pharmacokinetic studies of TB-500 in humans with or without hepatic impairment. The PK data cited in compounding circles derives from animal models of thymosin beta-4 (the full 43-amino-acid molecule), not the TB-500 fragment specifically. Extrapolating animal full-molecule data to a human fragment in the setting of liver disease involves at least three layers of uncertainty.

The FDA's guidance on pharmacokinetics in hepatic impairment requires sponsors to conduct dedicated hepatic-impairment studies for any drug substantially cleared by the liver. TB-500 has never undergone this process because it is not an approved drug. It is compounded under 503A pharmacy rules and is used exclusively in a research or off-label clinical context.

Hepatic Impairment and Dosing: Practical Guidance Without a Label

Because no label exists, the compounding clinicians who prescribe TB-500 rely on first-principles reasoning, case series, and conservative clinical judgment. Here is how that reasoning works in practice.

Child-Pugh Classification as a Starting Framework

The Child-Pugh score (classes A, B, and C) stratifies hepatic reserve using bilirubin, albumin, INR, ascites, and encephalopathy. Most compounding physicians apply it to TB-500 dosing informally:

| Child-Pugh Class | Hepatic Reserve | Suggested Approach | |---|---|---| | A (5-6 points) | Mild impairment | Standard dose; monitor liver enzymes at baseline and 4 weeks | | B (7-9 points) | Moderate impairment | Reduce dose by 25-50%; extend interval to weekly or biweekly | | C (10-15 points) | Severe impairment | Avoid use; no safety or clearance data |

This table represents clinical consensus among compounding practitioners, not published trial data. Treat it as a starting point for conversation with your prescribing clinician, not a prescriptive protocol.

Why Dose Reduction Is Reasonable Even Without Data

Several indirect lines of evidence support conservative dosing in hepatic impairment. First, the liver synthesizes albumin, and albumin binds many peptide fragments in transit. When albumin is low (as in Child-Pugh B or C disease), the unbound fraction of any peptide increases, raising effective exposure. Second, reduced hepatic peptidase activity means slower degradation and a longer effective half-life. Third, hepatic impairment often co-occurs with reduced renal perfusion (hepatorenal syndrome spectrum), compounding clearance delays.

For context, the FDA's general hepatic-impairment guidance notes that for renally cleared drugs with secondary hepatic metabolism, even Child-Pugh A impairment can meaningfully alter exposure. TB-500 fits this mixed-clearance profile.

Women-Specific Hepatic Conditions That Change the Calculus

Women are not a homogeneous group for liver disease. Several female-prevalent conditions create specific TB-500 risk contexts.

PCOS and Nonalcoholic Fatty Liver Disease

Women with PCOS have a two- to threefold higher prevalence of nonalcoholic fatty liver disease (NAFLD) compared with age-matched controls, driven by insulin resistance, hyperandrogenism, and visceral adiposity. NAFLD exists on a spectrum from simple steatosis to nonalcoholic steatohepatitis (NASH) and eventually cirrhosis. A woman with PCOS who is considering TB-500 for inflammatory tissue recovery may already have subclinical hepatic impairment she does not know about.

Before starting TB-500, women with PCOS should have a liver function panel (ALT, AST, GGT, bilirubin, albumin) and ideally a FIB-4 score calculated. The American Association for the Study of Liver Diseases (AASLD) guidance on NAFLD recommends screening high-risk metabolic populations. This is the same population most likely to be interested in metabolic peptide therapies.

Perimenopausal and Post-Menopausal Liver Changes

Estrogen is hepatoprotective. It suppresses hepatic stellate cell activation, reduces fibrogenesis, and modulates lipid metabolism in the liver. As estrogen declines during perimenopause, NAFLD incidence rises sharply in women who were previously at lower risk than men. Post-menopausal women have NAFLD prevalence approaching that of men, reversing the pre-menopausal sex protection.

A woman in her late 40s or 50s considering TB-500 for tendon repair or general tissue recovery may have developed hepatic steatosis during the perimenopausal transition without any symptoms. This makes baseline liver assessment non-negotiable before any peptide regimen.

Autoimmune Hepatitis and Primary Biliary Cholangitis

Both autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC) are significantly more common in women, with female-to-male ratios of approximately 4:1 for AIH and 9:1 for PBC. These conditions cause hepatic inflammation and progressive fibrosis. TB-500's theoretical immunomodulatory properties (thymosin family peptides have broad immune effects) have not been studied in the context of autoimmune liver disease. The direction of any interaction, whether beneficial or harmful, is genuinely unknown.

Women with AIH or PBC should not use TB-500 outside of a supervised clinical protocol with a hepatologist co-managing their care.

Intrahepatic Cholestasis of Pregnancy

This is addressed in the pregnancy section below, but cholestasis of pregnancy leaves some women with residual hepatic dysfunction after delivery. If you experienced intrahepatic cholestasis of pregnancy (ICP), tell your prescribing clinician before any peptide therapy is considered postpartum.

Pregnancy, Lactation, and Contraception

TB-500 is contraindicated in pregnancy.

There are no human data on thymosin beta-4 or TB-500 use during pregnancy. Animal studies are limited and were not designed to assess teratogenicity. The peptide's role in cell migration, angiogenesis, and progenitor cell recruitment means it theoretically could interfere with placentation or fetal organogenesis, though this has not been directly tested.

Because TB-500 is a research compound without an FDA pregnancy category under the old system, and has not been assessed under the FDA's current Pregnancy and Lactation Labeling Rule (PLLR), no formal "Category" label exists. Compounding clinicians categorize it as high-risk by default given the complete absence of human gestational data.

Practical rules:

• Stop TB-500 at least one full cycle (4 to 6 weeks) before attempting conception, with a reasonable clinician extending that to 3 months given the unknown half-life in liver disease.
• Use reliable contraception throughout any TB-500 course if you are in reproductive years and not actively trying to conceive.
• If you discover you are pregnant while on TB-500, stop immediately and contact your OB-GYN. No panic is warranted, but documentation and monitoring are appropriate.

Lactation: No data on TB-500 transfer into breast milk exist. Peptides of this molecular weight may be degraded in the infant's gut even if transferred, but "may be degraded" is not the same as "confirmed safe." Avoid TB-500 while breastfeeding. Pump-and-dump strategies are not validated for this compound.

Postpartum note: Women who had intrahepatic cholestasis during pregnancy (ICP) and are now postpartum may have residual liver enzyme abnormalities. Wait for confirmed normalization of liver function before considering TB-500, and disclose the ICP history to your prescribing clinician.

Who This Is Right For (and Not Right For), by Life Stage

Reproductive Years (Ages 18-40)

TB-500 may be considered in non-pregnant women with musculoskeletal injury or inflammatory conditions if liver function is normal. PCOS is common in this group; screen for NAFLD before prescribing. Contraception requirement is firm. Women on oral contraceptives should know that OC-associated changes in hepatic protein synthesis (increased sex hormone-binding globulin, altered albumin) could theoretically affect peptide clearance, though no data confirm this.

Trying to Conceive

Stop TB-500. There is no safe window during active fertility treatment. Ovarian stimulation, implantation, and early embryogenesis all involve the same cell-migration and angiogenesis pathways TB-500 theoretically modulates.

Perimenopause (Typically Ages 45-55)

This group has the highest undiagnosed NAFLD burden and the most rationale for tissue-repair support given estrogen decline. They also face the highest liver-disease risk from metabolic transition. Baseline liver panel and FIB-4 are mandatory. If Child-Pugh A, a cautious reduced-dose trial with monthly monitoring is reasonable. If Child-Pugh B or worse, defer.

Post-Menopause

Same considerations as perimenopause but with longer cumulative estrogen deficiency and potentially more advanced hepatic steatosis. Add a DEXA scan to the workup if osteoporosis is a co-concern, since both bone loss and tissue fragility motivate TB-500 interest in this group.

Women with Chronic Liver Disease

Cirrhosis (any cause) represents a hard boundary. Until pharmacokinetic data exist in this population, use of TB-500 in Child-Pugh B or C disease cannot be justified outside a formal research protocol.

Monitoring Parameters in Women with Hepatic Impairment

If your clinician decides a cautious TB-500 trial is appropriate in mild hepatic impairment, the following monitoring schedule reflects standard compounding-clinic practice:

Before Starting

• Complete metabolic panel (ALT, AST, GGT, alkaline phosphatase, bilirubin, albumin, total protein)
• INR if cirrhosis is suspected
• FIB-4 score calculation (age x AST divided by platelet count x square root of ALT)
• Pregnancy test if in reproductive years
• Disclosure of all concurrent medications, particularly hepatotoxic agents

During the Cycle (Weeks 2 and 4)

• Repeat liver enzymes
• Symptom check: new fatigue, right upper quadrant discomfort, dark urine, jaundice
• Any two-fold elevation above baseline warrants stopping TB-500

After the Cycle

• Liver panel at 4 weeks post-completion
• Review before any repeat cycle

The Evidence Gap: What We Know, What We Are Guessing

The following framework is the WomanRx editorial board's original synthesis of what is directly studied versus extrapolated in the TB-500 and hepatic impairment question. No single source publishes it this way.

Directly studied (in animals or small human trials):

• Thymosin beta-4's actin-sequestering mechanism in cell culture and animal models
• Cardiac repair effects of thymosin beta-4 in post-MI animal models and a small human cardiac trial reviewed in Goldstein et al. (2012)
• NAFLD prevalence in PCOS from epidemiological cohort data

Extrapolated from related peptide pharmacology:

• Hepatic peptidase contribution to TB-500 clearance
• Albumin-binding effects on unbound fraction in hypoalbuminemic states
• Half-life extension in reduced hepatic mass

Genuinely unknown:

• Any pharmacokinetic parameter of TB-500 (not thymosin beta-4) in humans
• Sex-specific differences in TB-500 metabolism
• Interaction between TB-500 and estrogen status
• Safe dose in any degree of hepatic impairment
• Teratogenicity, embryotoxicity, or lactation transfer

"Women have been historically underrepresented in peptide therapy trials," notes Dr. Elena Vasquez, WomanRx editorial board reviewer and women's-health clinician. "With TB-500, we are working with animal data extrapolated to a human fragment, then further extrapolated to women with liver disease. That is three layers of assumption, and clinicians prescribing this compound should be transparent about each one."

As ACOG has emphasized in its guidance on off-label drug use, shared decision-making requires that clinicians clearly communicate the difference between evidence-based prescribing and clinical judgment in the absence of trials. TB-500 in hepatic impairment is the latter.

Drug Interactions Relevant to Women with Liver Disease

TB-500 is not known to inhibit or induce CYP enzymes. However, women with hepatic impairment are often on multiple medications, and several interactions warrant attention:

• Warfarin: Hepatic impairment already extends warfarin half-life by reducing CYP2C9 activity. TB-500's theoretical effects on angiogenesis and wound healing could theoretically alter bleeding dynamics. Co-use warrants close INR monitoring.
• Oral contraceptives: OCs are hepatically metabolized. In hepatic impairment, OC exposure increases and hepatotoxicity risk rises. This is a separate concern from TB-500, but the combination requires hepatologist input.
• Immunosuppressants (tacrolimus, mycophenolate): Women with autoimmune hepatitis on immunosuppression should not add a peptide with unknown immunomodulatory properties without specialist review.
• GLP-1 receptor agonists: Women on semaglutide or tirzepatide for weight or PCOS management may be simultaneously improving hepatic steatosis. TB-500 has not been studied in combination with GLP-1 agents. No known pharmacokinetic interaction exists, but the combination is untested.

How to Talk to Your Clinician

Most conventional physicians have not heard of TB-500. If you are seeing a compounding-pharmacy-affiliated clinician or a functional medicine provider who is familiar with peptide therapy, bring the following to your appointment:

1. Your most recent liver function panel results, or request one before the visit.
2. A list of all medications, supplements, and hormones you take.
3. Your menstrual status or menopause stage.
4. A direct question: "Given my liver function, what dose reduction are you applying and why, and what monitoring will we do?"
5. A specific question about contraception requirements if you are in reproductive years.

If your clinician cannot answer those questions specifically, that is diagnostic information about the quality of oversight you are receiving.

The FDA's compounding pharmacy guidance makes clear that 503A compounded drugs are not FDA-approved and have not undergone the safety and efficacy review required of approved drugs. That does not make them automatically unsafe, but it does mean the burden of individualized clinical judgment falls entirely on your prescribing clinician and on you as an informed patient.